Oncorus, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Craig R. Jalbert CIRA
- Full Time Employees
- 64
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 50 Hampshire Street Cambridge MA United States of America 02139
- IPO Date
- Oct 2, 2020
- CIK
- 0001671818
- Website
- oncorus.com
- Similar Companies
- Business
- Oncorus, Inc. (ONCR) is a clinical-stage biopharmaceutical company that develops viral immunotherapies, including intravenously and intratumorally administered oncolytic viruses, to treat cancer patients by selectively killing tumor cells and stimulating antitumor immunity; its pipeline features ONCR-021, a self-amplifying RNA encoding an optimized Coxsackievirus 21A genome encapsulated in lipid nanoparticles for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma; ONCR-788, encoding a modified Seneca Valley Virus for small cell lung cancer and neuroendocrine cancers; and ONCR-719 from its herpes simplex virus platform. The company, founded in 2015 and headquartered in Andover, Massachusetts, previously operated in the United States with additional facilities in Cambridge, Massachusetts, targeting the oncology sector with a focus on immuno-oncology therapies. In June 2023, Oncorus initiated a workforce reduction impacting substantially all employees, approved a plan of liquidation and dissolution pending stockholder approval, filed for Chapter 11 bankruptcy which converted to Chapter 7, sold its intellectual property assets including over 35 patents through an out-of-court process managed by Hilco Streambank, delisted from Nasdaq, and ceased operations with common shares cancelled and a final liquidating distribution of $0.13933 per share paid in December 2023.
Why Is Oncorus (ONCR) Stock Down 27% Today?
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
Oncorus to Participate in Upcoming Investor Conferences
Oncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the Upgrade
Oncorus to Present at Chardan's 6th Annual Genetic Medicines Conference
Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Here's Why Oncorus, Inc. (ONCR) Looks Ripe for Bottom Fishing
Oncorus to Present at the Jefferies Global Healthcare Conference
Oncorus to Present at the H.C. Wainwright Global Investment Conference
Oncorus to Present at the Maxim Group 2022 Virtual Growth Conference
Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference
Oncorus to Present at the Jefferies London Healthcare Conference
Why Did Oncorus Shares Slump To 52-Week Low Today?
Why Oncorus Stock Is Crashing Today
Oncorus, Gaeta Therapeutics Ink Cancer Candidate Licensing Agreement
Wall Street Analysts Predict a 201% Upside in Oncorus, Inc. (ONCR): Here's What You Should Know
Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic
Oncorus Appoints Eric Rubin, M.D. to its Board of Directors
Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788
Oncorus Inc.: Undervalued Cancer Viral Immunotherapy Opportunity